Antibody-drug Conjugates (ADC)

Val-Cit-PABC-Ahx-May TFA is a cleavable linker designed for use in the construction of antibody-drug conjugates (ADCs). This compound facilitates targeted drug delivery, allowing for the selective release of therapeutic agents upon internalization by cancer cells. It is particularly valuable in research applications focused on optimizing ADC formulations and enhancing therapeutic efficacy.

Bromoacetamide-PEG4-DBCO is an efficient ADC linker that facilitates the synthesis of antibody-drug conjugates. This compound features a bromoacetamide moiety for selective labeling and a DBCO group for click chemistry applications. It is ideal for enhancing the therapeutic efficacy of targeted cancer treatments by enabling stable conjugation to antibodies. This linker is suitable for a variety of research applications focused on drug delivery systems and cancer therapeutics.

Propargyl-NH-PEG3-C2-NHS ester is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This reagent features a propargyl group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its unique properties make it a valuable tool for developing targeted therapies in cancer research and drug delivery systems.

Propargyl-PEG7-NHS ester is a PEG-based linker designed for use in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This cleavable linker features an alkyne group, facilitating copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its versatility and efficiency make it a valuable tool in the development of targeted therapeutics and bioconjugates for cancer research and drug delivery applications.

BCN-PEG4-HyNic is a cleavable linker designed for antibody-drug conjugate (ADC) synthesis, featuring a four-unit polyethylene glycol (PEG) spacer. Its primary mechanism involves click chemistry, specifically through the strain-promoted alkyne-azide cycloaddition (SPAAC) reaction, which facilitates the conjugation of azide-containing biomolecules. This reagent is ideal for researchers developing targeted therapeutics, enabling enhanced delivery and reduced systemic toxicity of cytotoxic drugs in cancer therapy.

Mal-PEG4-VCP-NB is a degradable antibody-drug conjugate (ADC) linker featuring a maleimide moiety, four polyethylene glycol (PEG) units, and a valproyl carbamate (VCP) nitrobenzyl (NB) group. This compound facilitates efficient conjugation to thiol-containing molecules, thereby enhancing drug delivery to targeted cells. Mal-PEG4-VCP-NB is particularly valuable in the development of ADCs for cancer research, enabling precise therapeutic applications by allowing controlled release of cytotoxic agents in the tumor microenvironment.

MC-GGFG-NH-D-Lactic acid functions as an effective linker for antibody-drug conjugate (ADC) applications. This compound is designed to facilitate the conjugation of therapeutic agents to antibodies, enhancing the delivery and efficacy of targeted therapies. Its structural properties make it suitable for use in the development of innovative drugs aimed at improving cancer treatment outcomes.

Me-Tet-PEG2-COOH is an ADC linker featuring two PEG units and a tetrazine moiety. It facilitates a specific inverse electron demand Diels-Alder reaction (iEDDA) with trans-cyclooctene (TCO) derivatives, enabling efficient conjugation in antibody-drug conjugate (ADC) applications. This reagent is ideal for researchers aiming to enhance the targeting and delivery of therapeutic agents in cancer treatment and other bioconjugation studies.

Hydroxy-PEG10-Boc is an uncleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This reagent facilitates the conjugation of cytotoxic agents, such as Paclitaxel and Docetaxel, to antibodies, enhancing targeted delivery and therapeutic efficacy in cancer research. Its stability and biocompatibility make it a valuable tool for the development of innovative ADC formulations.

(2-pyridyldithio)-PEG4 acid is a cleavable polyethylene glycol (PEG) linker designed for use in antibody-drug conjugates (ADCs). This four-unit PEG linker facilitates the conjugation of therapeutic agents to antibodies, enabling controlled release and targeted delivery of drugs. Its unique properties enhance the stability and efficacy of ADCs, making it a valuable tool for research in targeted cancer therapies and other therapeutic applications.

Azido-C2-SS-PEG2-C2-acid is a cleavable polyethylene glycol (PEG) linker designed for use in antibody-drug conjugates (ADCs). It features an azide group that allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules. Additionally, this linker can participate in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN-modified compounds, enabling versatile bioconjugation applications in chemical biology and therapeutic development.

PDP-C1-Ph-Val-Cit is a cleavable linker specifically designed for antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents in targeted cancer therapy, enhancing the efficacy of ADCs while minimizing off-target effects. Its unique structure allows for stable attachment to antibodies while ensuring effective drug release in the tumor microenvironment, making it a valuable tool in cancer research and therapeutic development.

NO2-SPDMV-sulfo is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates selective attachment of therapeutic agents to antibodies, enhancing targeted delivery while minimizing systemic toxicity. Its chemical structure allows for effective release of the drug payload upon reaching the target site, making it valuable in cancer research and therapeutic development.

NHPI-PEG2-C2-Pfp ester is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This 2-unit PEG-based linker facilitates stable covalent attachment between antibodies and cytotoxic drugs, enhancing the therapeutic efficacy while minimizing systemic toxicity. Its unique structure allows for improved solubility and bioavailability, making it a valuable component in ADC development and research applications.

Fmoc-GGFG-PAB-PNP is a novel ADC linker designed to facilitate the synthesis of antibody-drug conjugates (ADCs). This compound promotes the effective delivery of cytotoxic agents directly to target cells, enhancing therapeutic efficacy while minimizing off-target effects. It is instrumental in research applications focused on developing targeted cancer therapies and improving drug delivery systems in biomedical research.

N-Boc-N-bis(PEG2-OH) is a PEG-based linker designed for use in antibody-drug conjugates (ADCs) and PROTAC synthesis. This cleavable linker facilitates the precise attachment of therapeutic agents to antibodies, enhancing targeted drug delivery while minimizing off-target effects. Its structure allows for efficient conjugation and release of the active component, making it suitable for a variety of applications in drug development and molecular biology research.

Amino-ethyl-SS-PEG3-NHBoc is a cleavable linker featuring a three-unit polyethylene glycol (PEG) structure, designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the attachment of cytotoxic agents to antibodies, allowing for targeted delivery and enhanced therapeutic efficacy. Its cleavable nature enables the release of the therapeutic agent in the tumor microenvironment, making it a valuable tool for cancer research and drug development.

Val-Cit-PAB-DEA-COOH is an ADC linker designed for use in the synthesis of antibody-drug conjugates (ADCs). Its structure facilitates the controlled release of cytotoxic agents upon internalization by target cells, enhancing the specificity and efficacy of therapeutic applications. This compound is valuable in research focused on developing novel ADCs for cancer therapy.

mDPR(Boc)-Val-Cit-PAB is a cleavable linker specifically designed for antibody-drug conjugates (ADCs). It features a unique mechanism that facilitates the release of cytotoxic agents upon cellular internalization. This compound plays a critical role in enhancing the therapeutic efficacy of ADCs by improving selective drug delivery to targeted cancer cells. Its utility makes it a valuable reagent in cancer research and the development of targeted therapies.

Aminoethyl-SS-ethylalcohol is a glutathione-cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This reagent facilitates the release of cytotoxic agents in targeted therapy, ensuring selective delivery to cancer cells. Its biological activity contributes to the development of effective therapeutic strategies in cancer research and drug development.

Methylcyclopropene-PEG3-amine is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This three-unit polyethylene glycol (PEG) derivative facilitates the attachment of therapeutic agents to antibodies, enhancing the specificity and efficacy of ADCs. It has applications in cancer research and drug delivery systems, allowing for targeted therapy while minimizing off-target effects.

Di(4-morpholine-amide)-4-DTM-phenoxy(3,5-F)-O-PEG3-CH2COOH functions as a cleavable PEG-based linker for antibody-drug conjugates (ADCs). This compound facilitates the attachment of cytotoxic agents to antibodies while maintaining stability in circulation and enabling targeted delivery. Its strategic design enhances drug release in the targeted cellular environment, making it invaluable for research in cancer therapeutics and ADC development.

Biotin-PEG3-Me-Tet is an ADC linker characterized by the inclusion of three polyethylene glycol (PEG) units. This compound features a tetrazine group that enables a specific inverse electron demand Diels-Alder reaction (iEDDA) with trans-cyclooctene (TCO) derivatives. Biotin-PEG3-Me-Tet is particularly valuable in antibody-drug conjugate (ADC) research, facilitating targeted delivery and enhancing the therapeutic efficacy of biologically active compounds.

THP-SS-alcohol is a cleavable ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). Its unique structure facilitates the stable attachment of drug molecules to antibodies while enabling selective release in the target environment. This compound is essential for enhancing the efficacy and specificity of ADCs in cancer research and therapeutic applications.

N3-PEG2-C2-PFP ester is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs), targeting effective conjugation in drug delivery systems. This reagent features an azide group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules and supports strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN functionalized compounds. Its versatility and stability make it an essential tool for researchers developing advanced therapeutic agents.

Ald-Ph-amido-PEG3-C-COOH is a noncleavable linker designed for use in antibody-drug conjugates (ADCs). This compound facilitates stable attachment between the antibody and the cytotoxic drug, ensuring effective delivery to target cells. Its structure supports the development of ADCs for enhanced therapeutic efficacy in various cancers and other diseases.

Boc-PEG6-Val-Cit-PAB-OH is an ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of cytotoxic agents to antibodies, enhancing targeted delivery and efficacy in cancer research applications. Its hydrophilic PEG6 spacer promotes solubility and stability in biological systems, making it an essential tool in the development of novel cancer therapeutics.

Boc-aminooxy-ethyl-SS-propanol is a cleavable linker designed for use in antibody-drug conjugates (ADCs). It facilitates the selective release of cytotoxic agents upon internalization, enhancing the therapeutic efficacy of ADCs. This compound is critical for research applications focused on developing targeted cancer therapies.

DMAC-SPDB is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of cytotoxic drugs to antibodies, enhancing the targeted delivery and efficacy of chemotherapeutic agents. DMAC-SPDB is instrumental in advancing research in cancer therapeutics and ADC development.

PDdB-Pfp is a cleavable antibody-drug conjugate (ADC) linker designed for targeting the extracellular loop 1 (ECL1) of transmembrane 4 L6 family member 1 (TM4SF1). It facilitates the delivery of cytotoxic agents to specific cells expressing TM4SF1, enabling enhanced therapeutic efficacy while minimizing off-target effects. PDdB-Pfp is valuable for research in the development of targeted cancer therapies and other applications involving ADC technology.

Diazido-methyltetrazine tri-arm is a versatile ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective conjugation of cytotoxic agents to antibodies, enhancing therapeutic efficacy while minimizing off-target effects. Its structural features allow for efficient formation of stable linkages, making it suitable for various applications in ADC development and cancer research.

Me-Tet-PEG3-NHBoc is an ADC linker featuring a tetrazine moiety and three polyethylene glycol (PEG) units. This compound can participate in a specific inverse electron demand Diels-Alder (iEDDA) reaction with trans-cyclooctene (TCO) derivatives, facilitating targeted drug delivery in antibody-drug conjugates (ADCs). It is a valuable tool for researchers developing site-specific conjugation methodologies and enhancing the therapeutic efficacy of biologic therapies.

DBCO-PEG2-C2-acid is an efficient ADC linker that facilitates the synthesis of Antibody-Drug Conjugates (ADCs). This compound utilizes the DBCO (dibenzocyclooctyne) chemistry for site-specific conjugation, enhancing the stability and efficacy of the resulting ADCs. It is essential for researchers focused on developing targeted therapies in oncology and other therapeutic areas, allowing for improved drug delivery and minimized off-target effects.

Me-Tet-PEG3-NH2 is an ADC linker featuring three polyethylene glycol (PEG) units. This compound utilizes its tetrazine moiety to engage in a specific inverse electron demand Diels-Alder (iEDDA) reaction with cyclooctene (TCO) derivatives. It serves as a valuable tool in antibody-drug conjugate (ADC) development, facilitating the site-specific conjugation of cytotoxic agents to antibodies for targeted cancer therapy.

Ald-Ph-amido-PEG1-C2-Pfp ester is a non-cleavable 1-unit polyethylene glycol (PEG) linker designed for antibody-drug conjugation (ADC) applications. This linker facilitates the stable attachment of cytotoxic agents to antibodies, thereby enhancing the therapeutic efficacy in targeted cancer treatment. Its use allows for improved pharmacokinetics and minimized systemic toxicity, making it valuable in the development of innovative biopharmaceuticals.

TCO-GK-PEG4-NHS ester is an ADC linker that facilitates the synthesis of [18F]AlF-NOTA-Tz-TCO-GK-2Rs15d, which exhibits high affinity and immunoreactivity for the HER2 target. This compound features a TCO group that participates in inverse electron demand Diels-Alder (iEDDA) click chemistry reactions with tetrazine-containing molecules, allowing for precise bioconjugation applications in targeted therapies. It is suitable for research involving antibody-drug conjugates and the development of advanced molecular imaging techniques.

Acid-propionylamino-Val-Cit-OH is a cleavable linker designed for the development of antibody-drug conjugates (ADCs). It facilitates targeted delivery of cytotoxic agents to specific cells, enhancing therapeutic efficacy while minimizing off-target effects. This compound is widely utilized in cancer research and drug development, allowing for precise control over drug release in therapeutic applications.

Me-Tet-PEG2-NHS is an ADC linker designed for targeted drug delivery. This compound features a tetrazine group capable of participating in inverse electron demand Diels-Alder (iEDDA) reactions with TCO-modified molecules. Its two PEG units enhance solubility and stability, making it suitable for applications in antibody-drug conjugate (ADC) development and bioorthogonal labeling strategies in chemical biology.

BnO-PEG6-OH is a non-cleavable polyethylene glycol (PEG) linker designed for the synthesis of antibody-drug conjugates (ADCs). This 6-unit PEG compound enhances the stability and solubility of ADCs, facilitating targeted drug delivery. Additionally, BnO-PEG6-OH serves as a versatile linker in the development of PROTACs, enabling precise modulation of protein degradation pathways for various research applications.

Me-Tet-PEG4-NHBoc is an ADC linker characterized by the presence of four PEG units and a Tetrazine moiety. It is designed to facilitate a specific inverse electron demand Diels-Alder reaction (iEDDA) with TCO-containing compounds. This functionality enables effective conjugation in antibody-drug conjugate (ADC) applications, enhancing targeted delivery and efficacy in cancer research and other therapeutic areas.

Dimethylamine-SPDB is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This reagent enables the selective release of therapeutic agents upon internalization and subsequent cleavage within target cells, enhancing the efficacy of ADCs. It is particularly useful in research applications focused on targeted cancer therapies and drug delivery systems.

Tr-PEG6-OH is a non-cleavable polyethylene glycol (PEG) linker consisting of six units, designed for use in the synthesis of antibody-drug conjugates (ADCs). This linker provides enhanced solubility and stability, ensuring effective delivery of therapeutic agents while maintaining the binding affinity of the antibody. Tr-PEG6-OH is ideal for research applications focused on the development of targeted cancer therapies and bioconjugation techniques.

SMCC-NH-CH2-triazole-PEG8-oxydiacetamide-Lys(MTT)-PAB is an ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features a linker that facilitates the attachment of active pharmaceutical agents to antibodies, enhancing specificity and efficacy in targeted therapy applications. It is suitable for various research applications aimed at developing novel ADC formulations for cancer treatment and other therapeutic areas.

Me-Tet-PEG4-NHS is an ADC linker featuring four PEG units that facilitates targeted drug delivery. This compound contains a Tetrazine moiety, enabling it to undergo a specific inverse electron demand Diels-Alder reaction (iEDDA) with trans-cyclooctene (TCO) derivatives. Its key biological activity lies in enhancing the stability and efficacy of antibody-drug conjugates (ADCs), making it suitable for applications in cancer research and therapeutic development.

L-Val-D-Cit-PAB is an antibody-drug conjugate (ADC) linker that facilitates the synthesis of highly targeted therapeutics. This compound is characterized by its ability to connect antibodies with cytotoxic drugs, enhancing the delivery of biologically active agents to specific cells. L-Val-D-Cit-PAB is particularly useful in cancer research, where it aids the development of ADCs to improve selectivity and efficacy in tumor treatment.

Aminooxy-PEG4-alcohol is a non-cleavable linker that consists of a four-unit polyethylene glycol (PEG) chain, primarily targeting antibody-drug conjugates (ADCs). It serves as a versatile linker in the synthesis of ADCs and can also be employed in the development of proteolysis-targeting chimeras (PROTACs). This reagent enhances the stability and solubility of conjugated drugs, facilitating targeted delivery in therapeutic applications.

SPDB-sulfo is a glutathione-cleavable linker specifically designed for antibody-drug conjugates (ADCs). It facilitates the selective release of cytotoxic agents in tumor cells, enhancing the therapeutic efficacy of the ADCs while minimizing systemic toxicity. This linker is essential in the development of targeted cancer therapies, allowing for precise delivery of drugs to malignant tissues.

DBCO-S-S-acid is a cleavable linker designed for the construction of antibody-drug conjugates (ADCs). It features a DBCO group that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, allowing for selective and efficient conjugation. This reagent is essential in bioconjugation strategies aimed at enhancing targeted therapeutic delivery in cancer research and other therapeutic applications.

PEG12-Tos is a non-cleavable linker utilized in the synthesis of antibody-drug conjugates (ADCs). This PEG-based linker facilitates the construction of stable ADCs, improving the therapeutic efficacy of the conjugated drug while minimizing off-target effects. In addition, PEG12-Tos serves as a versatile linker in the development of PROTACs, enhancing cell permeability and solubility, and expanding research applications in targeted protein degradation and therapeutic interventions.

Ala-Ala-Asn-PAB is a peptide-cleavable linker designed for use in antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents upon internalization by target cells, thereby enhancing the therapeutic efficacy of ADCs. Researchers can utilize Ala-Ala-Asn-PAB in studies focused on improving drug delivery mechanisms and evaluating the pharmacodynamics of ADC formulations.